Key result
Microvascular disease and cardiovascular comorbidities are linked to higher COVID-19 mortality risk.
Why the study?
Elderly, diabetic, hypertensive, and cardiovascular disease patients experience higher COVID-19 fatality rates, prompting a need to elucidate the biological and pathophysiological mechanisms underlying this heightened risk.
Underlying microvascular disease may provide a pathophysiological explanation for the increased mortality risk observed in COVID-19 patients with cardiovascular comorbidities.
Answers are grounded in this paper and cite their sources.
May explain excess COVID-19 mortality in comorbid patients; leaves open need for prospective validation before clinical application.
The majority of fatalities thus far in the COVID-19 pandemic have been attributed to pneumonia. As expected, the fatality rate reported in China is higher in people with chronic pulmonary disease (6.3%) and those who have cancer (5.6%). According to the American College of Cardiology Clinical Bulletin "COVID-19 Clinical Guidance for the CV Care Team", there is a significantly higher fatality rate in people who are elderly (8.0% 70-79 years; 14.8% ≥80 years), diabetic (7.3%), hypertensive (6.0%), or have known cardiovascular disease (CVD) (10.5%). We propose a biological reason for the higher mortality risk in these populations that is apparent. We further present a set of pathophysiological reasons for the heightened danger that could lead to therapies for enhanced management and prevention.
No takes yet. Share an insight, caveat, or question.
Bale et al. (2020) conducted a review in COVID-19 infection. Microvascular disease and cardiovascular comorbidities was evaluated on Fatality rate. Microvascular disease and other cardiovascular comorbidities are proposed to confer additional mortality risk in COVID-19 infection due to underlying pathophysiological mechanisms.
Synapse has enriched 10 related papers. Consider them for comparative context: